The somatopause is no indication for growth hormone therapy

Journal of Endocrinological Investigation

Volumn 22, Issue 5 SUPPL., 1999, Pages 137-141

  Von Werder, K ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Schlosspark Klinik   (Germany)

Author keywords

Growth hormone; Somatopause

Indexed keywords

HUMAN GROWTH HORMONE;

AGED; AGING; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS; PHYSIOLOGY; REFERENCE VALUE; REVIEW; SECRETION;

AGED; AGING; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; PITUITARY GLAND; REFERENCE VALUES; SECRETORY RATE;

EID: 0032609037     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Herman-Bonert V.S., Prager D., Melmed S. Growth hormone. In: Melmed S. (Ed.), The pituitary. Blackwell Science, Cambridge, MA, 1995, p. 98.
2. Vance M.L., Kaiser D.L., Evans W.S., Furlanetto R., Vale W., Rivier J., Thorner M.O. Pulsatile growth hormone secretion in normal man during a continuous 24 hour infusion of growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion. J. Clin. Invest. 1985, 75: 1584.
3. nd Annual Meeting of The Endocrine Society, Atlanta, GA, 1990, p. 51.
4. Baumann G., Shaw MA, Brumbaugh R.C., Schwartz J. Short stature and decreased serum growth hormone-binding protein in the Mountain Ok people of Papua New Guinea. J. Clin. Endocrinol. Metab. 1991, 72: 1346.
5. Kelijman M. Age-related alterations of the growth hormone/insulin-like-growth-factor I axis. J. Am. Geriatr. Soc. 1991, 39: 295.
6. Young V.R., Steffee W.P., Pencharz P.B. Total human body protein synthesis in relation to protein requirements at various ages. Nature 1975, 253: 192.
7. Novack L.P. Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years. J. Gerontol. 1972, 27: 438.
8. Enzi G., Gasparo M., Biondetti P., Fiore D., Semissa M., Zurlo F. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am. J. Clin. Nutr. 1986, 44: 739.
9. Kalkhoff R.K., Hartz A.H., Rupley D., Kissebah A.H., Kelber S. Relationship of fat distribution to blood pressure, carbohydrate tolerance, and plasma lipids in healthy obese women. J. Lab. Clin. Med. 1983, 102: 621.
10. Marcus R., Butterfield G., Holloway L., Gilliland L., Baylink D.J., Hintz R.L., Sherman B.M. Effects of short term administration of recombinant human growth hormone to elderly people. J. Clin. Endocrinol. Metab. 1990, 70: 519.
11. Kaiser F.E., Silver A.J., Morley J.E. The effect of recombinant human growth hormone on malnourished older individuals. J. Am. Geriatr. Soc. 1991, 39: 235.
12. von Werder K. Growth hormone therapy in prostatic cancer: preliminary results. In: Ranke M.B., Christiansen J.S. (Eds.), The complexity of endocrine systems. J&J Verlag, Mannheim, 1996, p. 163.
13. Rudman D.M., Feller A.G., Nagraj H.S., Gergans G.A., Lalitha P.Y., Goldberg A.F., Schlencker R.A., Cohn L., Rudman I.W., Mattson D.E. Effect of human growth hormone in men over 60 years old. N. Engl. J. Med. 1990, 323: 1.
14. Jørgensen J.O.L. Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocr. Rev. 1991, 12: 189.
15. Alexander L., Appleton D., Hall R., Ross W.M., Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin. Endocrinol. (Oxf.) 1980, 12: 71.
16. Bengtsson B.-Å, Edén S., Ernest I., Oden A., Sjögren B. Epidemiology and long-term survival in acromegaly. Acta Med. Scand. 1988, 223: 327.
17. Lieberman S.A., Hoffman A.R. Sequelae to acromegaly: reversibility with treatment of the primary disease. Horm. Metab. Res. 1990, 22: 313.
18. Rajasoorya C., Holdaway I.M., Wrightson P., Sott D.J., Ibbertson H.K. Determinants of clinical outcome and survival in acromegaly. Clin. Endocrinol. 1994, 41: 95.
19. Delhougne B., Deneux C., Abs R., et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J. Clin. Endocrinol. Metab. 1995, 80: 3223.
20. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279: 563.